Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial

In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent SARS-CoV-2 mRNA vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wildtype spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titer...

Descripción completa

Detalles Bibliográficos
Autores principales: Branche, Angela R., Rouphael, Nadine G., Losada, Cecilia, Baden, Lindsey R., Anderson, Evan J., Luetkemeyer, Anne F., Diemert, David J., Winokur, Patricia L., Presti, Rachel M., Kottkamp, Angelica C., Falsey, Ann R., Frey, Sharon E., Rupp, Richard, Bäcker, Martín, Novak, Richard M., Walter, Emmanuel B., Jackson, Lisa A., Little, Susan J., Immergluck, Lilly C., Mahgoub, Siham M., Whitaker, Jennifer A., Babu, Tara M., Goepfert, Paul A., Fusco, Dahlene N., Atmar, Robert L., Posavad, Christine M., Netzl, Antonia, Smith, Derek J., Telu, Kalyani, Mu, Jinjian, Makowski, Mat, Makhene, Mamodikoe K., Sonja, Crandon, Montefiori, David C., Roberts, Paul C., Beigel, John H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081431/
https://www.ncbi.nlm.nih.gov/pubmed/37034641
http://dx.doi.org/10.1101/2023.01.31.23285306

Ejemplares similares

Ejemplares similares